Control Bionics strikes capital-light US deal to expand iOS speech device range

An announcement from Control Bionics Ltd. ( (AU:CBL) ) is now available.

Control Bionics’ U.S. subsidiary has entered an exclusive joint venture-style agreement with NextLevel Assistive Technology to manufacture, assemble, and distribute new UnoTouch Omni and Active iOS-based speech-generating devices in the United States. NextLevel will design and fund the chassis and components, while Control Bionics will serve as FDA Manufacturer of Record, complete final assembly, and leverage its existing distributor network to bring the devices to market.

The capital-light structure is designed to be accretive to revenue, profit, and cash flow, giving Control Bionics exposure to the fast-growing, high-volume iOS tablet-based SGD segment estimated at US$100–150 million annually. The partnership is intended to complement the company’s higher-complexity NeuroNode platform and broaden its AAC offering, with non-binding discussions contemplating potential annual volumes of 1,000–1,500 devices, although there is no certainty these volumes or definitive distribution agreements will be achieved.

The most recent analyst rating on (AU:CBL) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Control Bionics Ltd. stock, see the AU:CBL Stock Forecast page.

More about Control Bionics Ltd.

Control Bionics Limited is an Australia-based assistive technology company that develops augmentative and alternative communication solutions, including its NeuroNode neural-interface platform. Through its U.S. subsidiary and distributor-led model, the company focuses on supplying speech-generating devices to the American AAC market, targeting users with complex communication needs.

Average Trading Volume: 488,307

Technical Sentiment Signal: Buy

Current Market Cap: A$25.13M

For an in-depth examination of CBL stock, go to TipRanks’ Overview page.